Introduction to Membrane Protein Antibody Discovery and Hybridoma

Membrane proteins are involved in a variety of normal physiological processes, and their abnormal function is associated with a wide range of diseases. The development of membrane protein antibodies is bound to bring new breakthroughs in the diagnosis and treatment of a range of diseases. One of the key technologies in the development of membrane protein antibodies is to obtain stable membrane protein immunogens with natural protein conformations. Creative Biolabs provides a comprehensive research platform for your membrane protein antibody development.

What is hybridoma technology?

B cells can secrete and express antibodies, but they cannot be passed on indefinitely in vitro. Myeloma cells, on the other hand, are permanently transmissible tumor cells. Based on cell fusion technology, scientists have obtained hybridoma cells by organically combining two types of cells. As a result, hybridoma cells possess both the antibody expression function of B cells and the infinite transmission function of myeloma cells, allowing the permanent production of monoclonal antibodies.

Generally speaking, the process of producing monoclonal antibodies using hybridoma technology consists of five main steps, including immunogen preparation, immunization of experimental animals with the immunogen, preparation of hybridoma cells, screening and cloning of hybridoma cells, and mass production of monoclonal antibodies using hybridoma cells.

The advantages of hybridoma technology for monoclonal antibody production are mainly that the whole experimental operation and conditions are relatively simple, the threshold is relatively low, and highly active monoclonal antibodies can be obtained. The disadvantages are the high workload and the long time required.

Membrane Protein Antibodies and Hybridoma

Hybridoma technology is well-established for antibody production. Therefore, it is more suitable for the field of membrane protein antibody development. The primary difficulty in membrane protein antibody development is the isolation and purification of immunogens with natural protein conformations. For antibody development using hybridoma technology, the higher the purity of the antigen used to prepare monoclonal antibodies, the higher the success rate of monoclonal antibody preparation experiments. Therefore, the preparation of membrane protein immunogens with high purity and activity is the key to the development of membrane protein antibodies using hybridoma technology. Currently, compliant membrane proteins have been obtained by lipid particle, nanodisk, and polymer technologies. Therefore, when using hybridoma technology to produce membrane protein antibodies, it is only necessary to select appropriate membrane protein isolation and purification methods according to the specific experimental project in order to obtain naturally active immunogenic proteins. The selection of immune animals is also crucial in the production of membrane protein antibodies. First of all, the selection of immune animals is an important means to obtain antibodies. Moreover, in the production of membrane protein antibodies, special experimental animals are selected according to specific research protocols, such as target protein-deficient mice, mice with human immunoglobulin genes, or even non-mouse-specific immune animals. Therefore, the production of membrane protein antibodies using hybridoma technology requires the development of appropriate experimental protocols based on the characteristics of the antibodies.

Creative Biolabs would like to share with you the key points and experiences in membrane protein antibody discovery and hybridoma technology to facilitate the smooth running of your project.

All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.

	USA: Europe: Germany:
	Call us at: USA: UK: Germany:
	Fax:
	Email: